bioRxivCell BiologyPreprint
Iron-loaded deferiprone can support full hemoglobinization of cultured red blood cells in the absence of transferrin
J. S. Gallego-Murillo, N. Yagcı, E. M. Pinho, A. Abeijon-Valle, A. Wahl, E. van den Akker, M. von Lindern
Abstract
Iron is an essential nutrient in mammalian cell cultures, conventionally supplemented as iron-loaded transferrin (holotransferrin). The high cost of human transferrin represents a challenge for the large scale production of cell therapies, such as cultured red blood cells. We evaluated the use of deferiprone, a cell membrane-permeable drug for iron chelation therapy, as an iron carrier for erythroid cultures. Iron-loaded deferiprone (Def3{middle dot}Fe3+) at a concentration of 52mol/L could fully replace holotransferrin during erythroblast differentiation into reticulocytes, the erythroid differentiation stage with maximal iron requirements. Reticulocytes cultured in presence of Def3{middle dot}Fe3+ or holotransferrin (1000g/mL) were similar with respect to expression of cell-surface markers CD235a and CD49d, hemoglobin content, and oxygen association/dissociation. Def3{middle dot}Fe3+ also supported expansion of the erythroid compartment in vitro, except for the first stage when hematopoietic stem cells committed to erythroblasts, in which a reduced erythroblasts yield was observed. This suggests that erythroblasts acquired the potential to process Def3{middle dot}Fe3+ as iron source for biosynthesis pathways. Replacement of holotransferrin by Def3{middle dot}Fe3+ was also successful in cultures of six myeloid cell lines (MOLM13, NB4, EOL1, K562, HL60, ML2). These results suggest that iron-loaded deferiprone can partially replace holotransferrin in chemically defined medium formulations for the production of cultured reticulocytes and proliferation of selected myeloid cell lines. This would lead to a significant decrease in medium cost that would improve the economic perspectives of the large scale production of red blood cells for transfusion purposes. Key pointsO_LIHolotransferrin limitations in erythroid cultures lead to lower erythroblast yields, impaired maturation and low enucleation efficiencies. C_LIO_LIIron-loaded deferiprone can replace holotransferrin in erythroblast expansion and differentiation cultures. C_LI
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: cell signaling & trafficking
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- MNC-RED a Chemically Defined Method to Produce Enucleated Red Blood Cells from Adult Peripheral Blood Mononuclear Cells
S. E. Zhang, E. E. Olivier, … E. E. Bouhassira·bioRxiv·Apr 25, 2019
- Use of dual electron probes reveals role of ferritin in erythropoiesis
M. A. Aronova, S. J. Noh, … R. D. Leapman·bioRxiv·Dec 19, 2019
- Large-scale in-vitro production of red blood cells from human peripheral blood mononuclear cells
S. J. Heshusius, E. Heideveld, … E. M. van den Akker·bioRxiv·Jun 18, 2019
- Expansion and differentiation of ex vivo cultured erythroblasts in scalable stirred bioreactors
J. S. Gallego-Murillo, G. Iacono, … S. A. Wahl·bioRxiv·Feb 11, 2022
- Metabolic profiling of cultured erythroblast for the production of transfusion-ready cultured red blood cells
Joan Sebastián Gallego‐Murillo, Ingeborg van Lakwijk, … Emile van den Akker·bioRxiv·Jun 2, 2026
- Iron deficiency affects early stages of embryonic hematopoiesis but not the endothelial to hematopoietic transition
Maya Shvartsman, Saygın Bilican, Christophe Lancrin·Scientific ReportsPeer-reviewed·Apr 23, 2019